Gland Pharma Ltd Share Price
As on 04 June 2026 at 20:13 IST
Gland Pharma Q1 FY26 Results:
Net profit rose 50% to ₹215.5 crores, compared to ₹144 crores in Q1 FY25. Total income in Q1 FY26 increased 8% to ₹1,563 crores from ₹1,453 crores in the same period last year.
About Gland Pharma Ltd
Gland Pharma Ltd is a leading pharmaceutical company producing complex generic injectables. The company provides high-quality injectable products for various therapeutic areas, including oncology, ophthalmology, and critical care. It operates in the pharmaceutical sector. The company was founded in 1978 in Hyderabad, India, making it decades old. Gland Pharma Ltd headquarters is in Hyderabad, Telangana, India. Gland Pharma’s main products include a wide range of injectables such as liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. The company also focuses on complex injectables, including peptides, suspensions, and hormonal products. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
22.96%
Over 6 Months
26.05%
Over 1 Year
40.49%
Over 3 Years
138.68%
Gland Pharma Ltd Summary
Close ₹2,232.30
Open ₹2,277
High ₹2,305.90
Low ₹2,222
Volume 2,55,715
Net Turnover (in Cr) ₹57.83
52Wk High ₹2,396
52Wk Low ₹1,573.60
52Wk High / Low
1,573.60
2,396
Gland Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹36,823.95
EPS (TTM) 79.87
Book Value (BV) 655.32
Div. Yield 0.89 %
P/E (TTM) 28.33
Price/Book Value 3.41
Delivery % 48.89 %
Face Value 1
Key Ratios
PE Ratio 24.07
PB Ratio 2.69
EV to Sales 5.78
PEG Ratio 5.44
ROA 11.14
ROE 11.62
Debt-Equity -
Net Profit Margin 26.47
Operating Profit Margin 40.27
Gland Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 5,830.11 | 5,834.96 | 3,865.06 | 4,624.65 | 3,597.65 |
| Total Expenses | 4,767.45 | 4,702.41 | 2,754.02 | 3,006.09 | 2,262.84 |
| Profit Before Tax | 1,062.66 | 1,132.54 | 1,054.58 | 1,618.55 | 1,334.81 |
| Profit After Tax | 698.53 | 772.46 | 781.04 | 1,211.66 | 996.96 |
| Operating Profit After Depreciation | 1,104.66 | 1,158.74 | 1,118.49 | 1,623.79 | 1,338.22 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 4,147.23 | 3,946.75 | 1,570.55 | 1,512.19 | 954.23 |
| Total Non Current Assets | 4,441.98 | 5,016.09 | 1,876.73 | 1,981.54 | 1,372.44 |
| Total Current Assets | 6,782.94 | 5,645.15 | 6,900.81 | 5,852.08 | 5,123.64 |
| Total Assets | 11,224.92 | 10,661.25 | 8,777.53 | 7,833.62 | 6,496.08 |
| Total Shareholder's Fund | 9,150.74 | 8,723.84 | 7,958.72 | 7,157.62 | 5,903.24 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 914.73 | 996.80 | 363.97 | 790.77 | 604.93 |
| Net Cash Used In Investing Activities | 1,717.87 | -1,749.19 | 1,211.19 | -999.31 | -1,520.42 |
| Net Cash Used In Financing Activities | -433.48 | -799.42 | 14.92 | 34.90 | 1,238.46 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,331.22 | 4,334.09 | 3,856.99 | 4,624.65 | 3,597.65 |
| Total Expenses | 2,865.64 | 2,928.60 | 2,752.13 | 3,005.61 | 2,262.80 |
| Profit Before Tax | 1,465.59 | 1,405.50 | 1,048.40 | 1,619.04 | 1,334.85 |
| Profit After Tax | 1,089.75 | 1,043.33 | 775.83 | 1,212.15 | 997 |
| Operating Profit After Depreciation | 1,488.42 | 1,413.34 | 1,112.28 | 1,624.28 | 1,338.26 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,744.99 | 1,693.73 | 1,570.55 | 1,512.19 | 954.23 |
| Total Non Current Assets | 4,654.65 | 4,969.76 | 1,884.84 | 1,989.70 | 1,372.99 |
| Total Current Assets | 5,766.96 | 4,571.32 | 6,888.34 | 5,844.44 | 5,123.07 |
| Total Assets | 10,421.62 | 9,541.09 | 8,773.18 | 7,834.14 | 6,496.06 |
| Total Shareholder's Fund | 9,755.10 | 8,995.29 | 7,953.30 | 7,158.23 | 5,903.28 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,073.67 | 1,135.97 | 367.89 | 791.29 | 604.93 |
| Net Cash Used In Investing Activities | 1,582.29 | -2,917.58 | 1,211.22 | -1,006.92 | -1,520.97 |
| Net Cash Used In Financing Activities | -339.54 | -7.40 | 14.92 | 34.90 | 1,238.46 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,742.79 | 1,695.36 | 1,486.88 | 1,505.62 | 1,424.91 |
| Total Expenses | 1,229.77 | 1,260.48 | 1,172.99 | 1,137.86 | 1,077.40 |
| Profit Before Tax | 505.80 | 362.12 | 283.92 | 312.74 | 288.33 |
| Profit After Tax | 366.68 | 261.48 | 183.68 | 215.48 | 186.54 |
| Operating Profit after Depreciation | 624.49 | 498.05 | 398.05 | 425.29 | 391.54 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,261.59 | 1,177.51 | 1,074.15 | 1,038.84 | 1,030.35 |
| Total Expenses | 753.88 | 755.89 | 699.26 | 679.99 | 636.23 |
| Profit Before Tax | 564.79 | 412.45 | 408.67 | 362.38 | 391.32 |
| Profit After Tax | 420.45 | 307.85 | 302 | 269.26 | 290 |
| Operating Profit after Depreciation | 614.07 | 481.83 | 457.48 | 413.59 | 437.84 |
Gland Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 2,200.90
S2 2,169.50
S3 2,117
Pivot 2,253.40
R1 2,284.80
R2 2,337.30
R3 2,368.70
Moving Average
20 SMA 2,114.47
50 SMA 1,882.64
100 SMA 1,821.30
200 SMA 1,841.98
Gland Pharma Ltd Corporate Actions
Gland Pharma Ltd
₹18.0/Share
Announcement Date 14 Aug 2025
Record Date 14 Aug 2025
Div Yield 1800%
Gland Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,789.45 | ₹4,29,349 |
| Divis Laboratories Ltd | ₹6,574.90 | ₹1,74,542.94 |
| Torrent Pharmaceuticals Ltd | ₹4,369.50 | ₹1,47,883.74 |
| Cipla Ltd | ₹1,375.05 | ₹1,11,076.61 |
| Zydus Lifesciences Ltd | ₹1,076.45 | ₹1,08,316.06 |
Gland Pharma Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Mirae Asset Midcap Fund | 1.69% |
| Mirae Asset ELSS Tax Saver Fund | 1.65% |
| ICICI Pru India Opportunities Fund | 1.50% |
| SBI Large & Midcap Fund | 1.44% |
| Mirae Asset Large & Midcap Fund | 1.37% |
Gland Pharma Ltd News
Gland Pharma allots 2.03 lakh equity shares under ESOS
02 Jun 2026, 04:34 pm
Volumes spurt at Gland Pharma Ltd counter
Gland Pharma Ltd notched up volume of 52.97 lakh shares by 14:14 IST on NSE, a 27.13 fold spurt over two-week average daily volume of 1.95 lakh shares
18 May 2026, 02:30 pm
Gland Pharma Ltd leads gainers in 'A' group
Great Eastern Shipping Company Ltd, Raymond Ltd, Arvind Ltd and Shipping Corporation of India Ltd are among the other gainers in the BSE's 'A' group today, 18 May 2026.
18 May 2026, 12:00 pm
Gland Pharma spurts as Q4 PAT jumps 97% YoY to Rs 367 crore
Gland Pharma surged 12.37% to Rs 2,098.05 after it has reported 96.62% increase in consolidated net profit to Rs 366.7 crore on a 22.31% rise in net sales to Rs 1,742.80 crore in Q4 FY26 over Q4 FY25.
18 May 2026, 09:36 am
Gland Pharma to hold AGM
On 25 August 2026
15 May 2026, 06:48 pm
Gland Pharma Ltd Stock Analysis
- Annual revenue for Gland Pharma Ltd decreased by 0.07% to ₹4,331.22 crore in FY 2025 from ₹4,334.09 crore in FY 2024.
- Annual Net Profit for Gland Pharma Ltd increased by 4.45% to ₹1,089.75 crore in FY 2025 from ₹1,043.33 crore in FY 2024.
- Promoter Shareholding in Gland Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 51.83% in December 2025 to 51.83% in March 2026.
- Gland Pharma Ltd delivered a 1-year return of 40.49% compared to the Nifty 50, which provided a return of -4.63% as of the last trading session.
- Gland Pharma Ltd share price moved up by 1.35% from its previous close of INR ₹2,232.30. The latest Gland Pharma Ltd share price is INR ₹2,262.50.
- Gland Pharma Ltd share price today has been at a low of 2,212 and a high of 2,276.70. Over the past 52 weeks, the Gland Pharma Ltd share price has seen a low of 1,573.60 and a high of 2,396.
About Gland Pharma Ltd
Gland Pharma Ltd is a leading pharmaceutical company producing complex generic injectables. The company provides high-quality injectable products across various therapeutic areas. These include oncology, ophthalmology, and critical care. Gland Pharma primarily operates under a business-to-business (B2B) model. It supplies its products to global markets.
Gland Pharma operates in the pharmaceutical sector. It has established itself as a significant player in the industry. The company was founded in 1978 making it decades old. It is now one of the largest and fastest-growing generic injectables companies with a global footprint.
Gland Pharma Ltd's headquarters is in Hyderabad, Telangana, India. The promoters of the company include Fosun Pharma Industrial Pte. Ltd with a significant 51.83% stake in the company. A team of professional managerial promoters manages the operations of the company. These include-
While Gland Pharma is a significant player in the generic injectables sector, it is not the largest in terms of market share. It also falls short in market capitalization. However, it holds a strong position in its niche market. This is particularly true for its manufacturing of complex injectables. This leadership is a testament to the company’s expertise and dedication to quality and innovation. The registered office of Gland Pharma Ltd is in Hyderabad, Telangana, and the registrar's office is in Mumbai, Maharashtra.
One of the primary impacts of Gland Pharma is its role in improving healthcare outcomes. The company’s high-quality injectable products are essential for treating various medical conditions. These include cancer, infections, and chronic diseases. These products are used in hospitals and healthcare facilities worldwide. They ensure that patients receive adequate and reliable treatments. Gland Pharma’s commitment to quality and safety ensures its products meet stringent regulatory standards. This gives healthcare professionals the confidence to use them in critical care settings.
Gland Pharma’s impact extends to the global pharmaceutical supply chain. The company operates under a business-to-business (B2B) model. It supplies its products to pharmaceutical companies and healthcare providers worldwide. This model allows Gland Pharma to reach various markets. These include the United States, Europe, Canada, Australia, and India.
The company’s focus on complex injectables has positioned it as a leader in the pharmaceutical industry. Gland Pharma specializes in producing a wide range of injectable products. These include liquid vials, lyophilized vials, pre-filled syringes, ampoules, and bags. These products are essential for various therapeutic areas. These include oncology, ophthalmology, and critical care.
Gland Pharma’s impact is also evident in its contributions to economic growth. The company provides employment opportunities to thousands of people. This supports livelihoods and contributes to economic development. Gland Pharma’s operations have a positive ripple effect on the communities where it operates, fostering economic growth and stability.
Innovation is a critical component of Gland Pharma’s impact. The company invests heavily in research and development to create advanced injectable products. These products are designed to meet the market's evolving needs. Gland Pharma’s focus on innovation ensures that it remains competitive and continues to offer solutions that enhance the performance and efficiency of its clients. The company’s R&D efforts focus on developing new formulations. They also aim to improve manufacturing processes. The company focuses on creating advanced solutions that cater to diverse applications.
Gland Pharma’s commitment to sustainability is another important aspect of its impact. The company recognizes the importance of environmental responsibility and is committed to reducing its environmental footprint. Gland Pharma focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste, reduce energy consumption, and use environmentally friendly materials.
The company’s strong leadership and management team have been instrumental in its success. Gland Pharma’s management team is committed to maintaining its reputation for quality and innovation, ensuring its continued success in the market.
Gland Pharma also engages in various corporate social responsibility initiatives. These initiatives aim to improve community health, education, and well-being. The company’s initiatives include supporting healthcare facilities, promoting environmental sustainability, and providing student scholarships. Gland Pharma’s focus on social responsibility reflects its belief that businesses have a role in creating a better world.
Gland Pharma operates in the pharmaceutical sector. It has established itself as a significant player in the industry. The company was founded in 1978 making it decades old. It is now one of the largest and fastest-growing generic injectables companies with a global footprint.
Gland Pharma Ltd's headquarters is in Hyderabad, Telangana, India. The promoters of the company include Fosun Pharma Industrial Pte. Ltd with a significant 51.83% stake in the company. A team of professional managerial promoters manages the operations of the company. These include-
- Yiu Kwan Stanley Lau
- Srinivas Sadu
- Yao Fang
- Jia Ai (Allen) Zhang
- Qiyu Chen
While Gland Pharma is a significant player in the generic injectables sector, it is not the largest in terms of market share. It also falls short in market capitalization. However, it holds a strong position in its niche market. This is particularly true for its manufacturing of complex injectables. This leadership is a testament to the company’s expertise and dedication to quality and innovation. The registered office of Gland Pharma Ltd is in Hyderabad, Telangana, and the registrar's office is in Mumbai, Maharashtra.
Impact of Gland Pharma Limited
Gland Pharma Ltd has made a significant impact on the pharmaceutical industry. This is especially true in the field of generic injectables. Established in 1978, the company has become one of the largest manufacturers of complex injectables. It serves global markets. The importance of Gland Pharma is evident in its contributions to healthcare and economic growth. It also plays a significant role in innovation.One of the primary impacts of Gland Pharma is its role in improving healthcare outcomes. The company’s high-quality injectable products are essential for treating various medical conditions. These include cancer, infections, and chronic diseases. These products are used in hospitals and healthcare facilities worldwide. They ensure that patients receive adequate and reliable treatments. Gland Pharma’s commitment to quality and safety ensures its products meet stringent regulatory standards. This gives healthcare professionals the confidence to use them in critical care settings.
Gland Pharma’s impact extends to the global pharmaceutical supply chain. The company operates under a business-to-business (B2B) model. It supplies its products to pharmaceutical companies and healthcare providers worldwide. This model allows Gland Pharma to reach various markets. These include the United States, Europe, Canada, Australia, and India.
The company’s focus on complex injectables has positioned it as a leader in the pharmaceutical industry. Gland Pharma specializes in producing a wide range of injectable products. These include liquid vials, lyophilized vials, pre-filled syringes, ampoules, and bags. These products are essential for various therapeutic areas. These include oncology, ophthalmology, and critical care.
Gland Pharma’s impact is also evident in its contributions to economic growth. The company provides employment opportunities to thousands of people. This supports livelihoods and contributes to economic development. Gland Pharma’s operations have a positive ripple effect on the communities where it operates, fostering economic growth and stability.
Innovation is a critical component of Gland Pharma’s impact. The company invests heavily in research and development to create advanced injectable products. These products are designed to meet the market's evolving needs. Gland Pharma’s focus on innovation ensures that it remains competitive and continues to offer solutions that enhance the performance and efficiency of its clients. The company’s R&D efforts focus on developing new formulations. They also aim to improve manufacturing processes. The company focuses on creating advanced solutions that cater to diverse applications.
Gland Pharma’s commitment to sustainability is another important aspect of its impact. The company recognizes the importance of environmental responsibility and is committed to reducing its environmental footprint. Gland Pharma focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste, reduce energy consumption, and use environmentally friendly materials.
The company’s strong leadership and management team have been instrumental in its success. Gland Pharma’s management team is committed to maintaining its reputation for quality and innovation, ensuring its continued success in the market.
Gland Pharma also engages in various corporate social responsibility initiatives. These initiatives aim to improve community health, education, and well-being. The company’s initiatives include supporting healthcare facilities, promoting environmental sustainability, and providing student scholarships. Gland Pharma’s focus on social responsibility reflects its belief that businesses have a role in creating a better world.
FAQ’s
What is the share price of Gland Pharma Ltd today?
Gland Pharma Ltd share price as on 4 Jun 2026 is ₹ 2262.5
What is the Market Cap of Gland Pharma Ltd?
The market cap of Gland Pharma Ltd stock is ₹36,823.95 Cr.
What is the PE Ratio of Gland Pharma Ltd?
The Price to Earnings (P/E) Ratio of Gland Pharma Ltd is 24.07
What is the PB Ratio of Gland Pharma Ltd?
The Price to Book (P/B) Ratio of Gland Pharma Ltd is 2.69
What is the 52 week high of Gland Pharma Ltd Share Price?
The 52 week high of Gland Pharma Ltd share price stands at ₹2,396
What is the 52 week low of Gland Pharma Ltd Share Price?
The 52 week low of Gland Pharma Ltd share price stands at ₹1,573.60
How can I buy shares of Gland Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Gland Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
